In conclusion, several PSMA targeted approaches in addition to radioligands to treat prostate cancer have been tested preclinically and shown promise in early phase clinical trials, but randomized clinical data supporting efficacy is still pending. This evidence concerns the gene FOLH1 and prostate carcinoma.